CDK4/6
3 drugsPredictive biomarker for patient selection in 6 indications
3
Approved Drugs
6
Indications
3
Companies
CDK4/6 is a precision-medicine biomarker linked to 3 FDA-approved targeted drugs from 3 companies, spanning 6 indications including Myelosuppression, Small Cell Lung Cancer, Breast Cancer. Explore the targeted therapies, indications, testing methods, and companies developing CDK4/6 drugs below.
Search CDK4/6 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting CDK4/6
CDK4/6 Indications
Myelosuppression Small Cell Lung Cancer Breast Cancer Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy Endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with inavolisib and fulvestrant following recurrence on or after completing adjuvant endocrine therapy